100
Participants
Start Date
October 29, 2018
Primary Completion Date
August 31, 2032
Study Completion Date
November 30, 2032
Rimiducid may be administered as indicated
Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
University of Pennsylvania, Philadelphia
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Johns Hopkins University, Baltimore
Sarah Cannon Research Institute at Tennessee Oncology, Nashville
Vanderbilt University Medical Center, Nashville
Wayne State - Karmanos Cancer Institute, Detroit
University of Chicago, Chicago
University of Kansas Cancer Center, Westwood
MD Anderson Cancer Center, Houston
Colorado Blood Cancer Institute, Denver
University of California, San Diego, San Diego
University of California San Francisco, San Francisco
University of California Davis, Davis
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
OTHER
Poseida Therapeutics, Inc.
INDUSTRY